Hepatology with ITSMED visual mark
The hepatology research group (HRG) is an integral part of the Institute of Health and Care Research: infection, immunity and inflammation.
We utilise state of the art laboratory facilities based in the Derriford Research Facility, and the world class clinical research strengths of the Faculty of Health and University Hospitals Plymouth NHS Trust.
We work in unison with the , at University Hospitals Plymouth NHS Trust, providing a full range and secondary, tertiary and community Hepatology services to the South West region, including assessment for liver transplantation, TIPS and liver cancer therapy.
The research team run several commercially sponsored clinical trials in hepatitis C therapy, non-alcoholic steatohepatitis (NASH), primary biliary cholangiopathy (PBC), alcoholic liver disease and liver failure amongst others, through the clinical research facilities of at Derriford Hospital.
Hepatology Research Group team photo


  • Boeira P, Tan H, Yates E & Dhanda A 2023 'Assessment of immune function and prediction of survival and infection in patients with severe alcoholic hepatitis: An exploratory study' JGH Open ,
  • Tavabie OD, Kronsten VT, Przemioslo R, McDougall N, Ramos K, Joshi D, Prachalias A, Menon K, Agarwal K & Heneghan MA 2023 'Satellite liver transplant centres significantly improve transplant assessment outcomes for patients with chronic liver disease but not hepatocellular carcinoma: a retrospective cohort study' Frontline Gastroenterology 14, (4) 334-342 ,
  • Allison MED, Verne J, Bernal W, Clayton M, Cox S, Dhanda A, Dillon JF, Ferguson J, Foster G & Gilmore I 2022 'Deaths from alcohol-related liver disease in the UK: an escalating tragedy' The Lancet 401, (10375) 418-420 ,
  • Sheridan DA, Shawa IT, Thomas EL, Felmlee DJ, Bridge SH, Neely D, Cobbold JF, Holmes E, Bassendine MF & Taylor-Robinson SD 2022 'Infection with the hepatitis C virus causes viral genotype-specific differences in cholesterol metabolism and hepatic steatosis' Scientific Reports 12, (1) ,
  • Bowlus CL, Galambos MR, Aspinall RJ, Hirschfield GM, Jones DEJ, Dörffel Y, Gordon SC, Harrison SA, Kremer AE & Mayo MJ 2022 'A phase II, randomized, open-label, 52-week study of seladelpar in patients with primary biliary cholangitis' Journal of Hepatology ,
  • Dhanda AD, Felmlee D, Boeira P, Moodley P, Tan H, Scalioni LDP, Lilly K, Sheridan DA & Cramp ME 2022 'Patients with moderate to severe COVID-19 have an impaired cytokine response with an exhausted and senescent immune phenotype' Immunobiology 227, (2) ,